In-house members
15
Total footprint
30,000sq ft
Our Old Market incubator hosts growing Deep Tech companies that have moved beyond proof of concept and are scaling their teams, typically 20–30 people strong.
This site serves as the main event venue of our Bristol campus — featuring the 1023 Bar, our community’s main stage for events and a gathering spot for informal meetups every Thursday.
Old Market members are breaking new ground in several science and engineering fields — from advanced sustainable materials to vaccine platforms and stem cell therapeutics.
With 30,000 sq ft of laboratory, office and meeting space, our Old Market incubator is a supportive, well-connected hub for growing Deep Tech companies.
This location also features a large event space, shared social spaces, and our favourite addition — the 1023 Bar, open every Thursday for the community.
Membership includes access to our platform of support, providing opportunities to attend workshops and events, connect with other founders, and find a mentor.





If you are looking for private lab and office space, get in touch to enquire about our current availability at Old Market or OMX, our newest Bristol incubator.



Travel between locations is measured in walking distance
Midland Rd & St Philips Rd
0.5 miles / 11 min
0.7 miles / 15 min

Hone Bio is revolutionising drug delivery using lipid nanoparticles (LNPs) and exploring their potential across multiple therapeutics, including cell and gene therapies, vaccines and autoimmune diseases. Its NanoPilot platform technology engineers LNPs to target specific cell types with extreme precision to optimise drug effectiveness by minimising off-target effects that tend to accumulate in the liver. This unlocks new possibilities for using LNPs to safely treat diseases in other parts of the body that require maximum target specificity in their drug delivery.

Epinal is revolutionising the detection and prevention of narcotic-impaired behaviour for safer roads, flights and workplaces. Utilising AI and novel biotechnology that mimics natural sensory mechanisms, it’s developing a handheld breathalyser that generates rapid results with extreme sensitivity and selectivity.

Invivo Healthcare is developing solutions to better understand and modulate human microbiomes, promoting long-term wellness and a sustainable future of healthcare. Its supplement therapeutics are plant, nutrient and microorganism-based, designed to lead the way in combating the rise of chronic diseases and a reductionist approach to medicine.




NuNano is advancing the field of atomic force microscopy with high-precision probes for nanometer-scale imaging. Its proprietary microfabrication processes produce reliable, high-quality probes with market-leading dimensional tolerances. It also provides dedicated support to its customers, from probe selection to storage, for a seamless user experience.

Kelpi is tackling plastic pollution by developing sustainable alternatives to single-use plastic packaging. It uses seaweed to create a unique bioplastic coating that provides a world-leading water barrier for new-generation packaging while being recyclable, biodegradable, and low carbon. By working with major food and drink, cosmetics and home care brands, Kelpi is already reducing reliance on fossil-fuel plastics and paving the way for a greener future in these industries.

Argonaute RNA is developing safe, reliable and targeted methods of temporarily silencing genes in different tissue cells. It does this via the proprietary modification of small interfering RNA (siRNA), using a novel stabilisation method to overcome previous obstacles to developing siRNA drugs for healthcare.




Uplift360 is developing chemical-based regeneration technologies to recover and reuse critical industrial materials such as carbon fibre and aramid. Its vision is to lead the way in circular economy innovation, creating a future where advanced materials are never wasted. Backed by the UK Defence and Security Accelerator (DASA), Luxembourg Government Directorate of Defence and Innovate UK, it enables circular and secure supply chains for high-performance sectors.

STL is leveraging its deep sector expertise as a venture builder to unlock the true value of innovation. Working alongside a network of investors and service providers, its strategic commercialisation process helps its customers build IP-led businesses that are viable and sustainable. It does this by applying streamlined entrepreneurial capabilities, in-house engineering and end-to-end due diligence for ventures bringing new technologies to life from basic concept to prototype demonstration, enhancing their growth and scalability.

Hone Bio is revolutionising drug delivery using lipid nanoparticles (LNPs) and exploring their potential across multiple therapeutics, including cell and gene therapies, vaccines and autoimmune diseases. Its NanoPilot platform technology engineers LNPs to target specific cell types with extreme precision to optimise drug effectiveness by minimising off-target effects that tend to accumulate in the liver. This unlocks new possibilities for using LNPs to safely treat diseases in other parts of the body that require maximum target specificity in their drug delivery.


